Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy

Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.

Authors

Kathryn A McGurk^{1

2}, Nagme Bilgehan¹, James S Ware^{1

2

3

4}

Affiliations

¹ National Heart and Lung Institute and MRC Laboratory of Medical Sciences, Imperial College London, UK (K.A.M., N.B., J.S.W.).
² Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA (K.A.M., J.S.W.).
³ Imperial College Healthcare NHS Trust, London, UK (J.S.W.).
⁴ Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK (J.S.W.).

No abstract available

Keywords: MYK-461; cardiomyopathy, hypertrophic; pharmacogenetics.

MeSH terms

Aminobutyrates / pharmacokinetics
Aminobutyrates / therapeutic use
Benzylamines
Cardiomyopathy, Hypertrophic* / drug therapy
Cardiomyopathy, Hypertrophic* / genetics
Humans
Pharmacogenetics*
Uracil / analogs & derivatives
Urea / analogs & derivatives

Substances

Aminobutyrates
omecamtiv mecarbil
MYK-461
Benzylamines
Uracil
Urea

Grants and funding